Zurück zu den Ergebnissen
Bibliografischer Datensatz · Ansicht und Zugriff
Artículo

Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method

Varsha Thorat et al · SpringerOpen · 2026

Ergänzendes Material verfügbar
Schnellübersicht. Prüfen Sie die grundlegenden Angaben und öffnen Sie den Inhalt über die Hauptschaltfläche. Die Seite zeigt nur die Informationen, die zum Identifizieren, Zitieren und Öffnen des Werks nötig sind.

Zugriff auf die Ressource

Öffnen Sie den Inhalt über die Hauptoption oder wählen Sie eine andere verfügbare Quelle.

DOAJ DOAJ Articles
Entrar por DOAJ
Hauptzugriff

Ergänzendes Material verfügbar

El enlace apunta a material asociado, anexos, tablas, datos o página complementaria. No se marca como libro/texto completo.
Material öffnen

Übersicht

Descripción general del contenido del recurso.

Abstract Background A sustainable and stability-indicating reversed-phase high-pressure liquid chromatography (RP-HPLC) method has been developed for the simultaneous estimation of chlorthalidone (CHL), Amlodipine (AML), and olmesartan medoxomil (OLM) in a combined cardiovascular dosage form by implementing an Analytical Quality by Design (AQbD) approach. Methods The RP-HPLC system employed a Sunniest C18 column (150 mm × 4.6 mm, 5.0 μm). The mobile phase consisted of 0.1% triethylamine in water (pH 2.4) and ethanol in a ratio of (65:35 v/v). At a flow rate of 1.5 mL/min. Detection was carried out at 245 nm using a photodiode array detector. Method optimization was performed using a Central composite design (CCD) under the AQbD framework. Forced degradation studies were conducted under acid, base, oxidative, thermal, and photolytic conditions to assess the method’s stability-indicating capability. Results The method showed good linearity in the 50–150% of test concentration with correlation coefficients (r2) exceeding 0.99 for all analytes. The method precision was found 98.9% for CHL and 101.4% for both AML and OLM. Forced degradation studies confirmed the method’s ability to resolve the active pharmaceutical ingredients from their degradation products. Well-separated, spectrally pure peaks were obtained for all analytes under all stress conditions, as confirmed by peak purity values greater than 0.950, indicating no interference from degradation products. The method demonstrated accuracy, precision, specificity, robustness as per the International Conference on Harmonization guidelines. Environmental sustainability was evaluated with GAPI (77), AMGS123, AGREEprep (0.69), and AGREE (0.81) scores, confirming its eco-friendly nature. Conclusions The integrated approach reduced solvent consumption, waste generation, and energy usage, supporting sustainable analysis. The method, validated as per ICH Q2(R2) guidelines, exhibited excellent linearity, precision, accuracy, specificity, robustness, and ruggedness. Forced degradation studies confirmed its stability-indicating capability. The present study highlights the need for incorporating antioxidants and implementing precautions against acidic and alkaline degradation, along with adopting proper packaging and storage strategies to enhance the stability of CHL, OLM, and AML in formulations prone to degradation.. Graphical abstract

Zitieren

Elegí el formato que necesitás y copiá la referencia al portapapeles.

APA 7

al, V. T. E. (2026). Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method. https://doi.org/10.1186/s43094-026-00985-w

MLA

al, Varsha Thorat et. "Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method." 2026. https://doi.org/10.1186/s43094-026-00985-w.

Chicago

al, Varsha Thorat et. 2026. "Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method.". https://doi.org/10.1186/s43094-026-00985-w.

Harvard

al, V. T. E. 2026, Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method, SpringerOpen, available at: https://doi.org/10.1186/s43094-026-00985-w [Accessed 7 Aug. 2026].

Teilen und drucken

Speichern Sie den Datensatz, kopieren Sie den Permalink oder drucken Sie ihn als PDF.

Referenz exportieren

Exportieren Sie den Datensatz in gängigen Formaten für Literaturverwaltungsprogramme.

Ressourcendetails

Bibliografische Angaben zur Prüfung, ob es sich um das richtige Material handelt.

Titel
Analytical quality by design (AQbD) approach for the simultaneous quantification of FDC in a cardiovascular drug by RP-HPLC method
Autor / Mitwirkende
Varsha Thorat et al
Verlag
SpringerOpen
Erscheinungsjahr
2026
ISSN
2314-7253
ISSN
2314-7253
Sprache
Inglés

Schlagwörter

Entdecken Sie über diese Schlagwörter weitere verwandte Ressourcen.

Kopiert